Global Drugs for HAE Market
授權報價
| Single User License | $3,480 USD |
| Multi User License | $5,220 USD |
| Corporate Users License | $6,960 USD |
完整報告名稱與涵蓋範圍
Global Drugs for HAE Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
報告摘要
According to our (Global Info Research) latest study, the global Drugs for HAE market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Drugs for Hereditary Angioedema (HAE) are treatments aimed at managing and preventing the recurrent swelling attacks caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH). Key therapies include C1-INH replacement (e.g., Berinert, Haegarda), kallikrein inhibitors (e.g., Ecallantide) to block bradykinin production, and bradykinin B2 receptor antagonists (e.g., Icatibant) to stop bradykinin from causing swelling.
This report is a detailed and comprehensive analysis for global Drugs for HAE market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drugs for HAE market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for HAE market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for HAE market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Drugs for HAE market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drugs for HAE
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drugs for HAE market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceuticals, BioCryst Pharmaceuticals, CSL Behring, Pharming Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Drugs for HAE market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
C1 Esterase Inhibitors
Kallikrein Inhibitors
Bradykinin Receptor Antagonist
Market segment by Application
Hospital and Clinic
Pharmacy
Other
Major players covered
Takeda Pharmaceuticals
BioCryst Pharmaceuticals
CSL Behring
Pharming Healthcare
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for HAE product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Drugs for HAE, with price, sales quantity, revenue, and global market share of Drugs for HAE from 2021 to 2026.
Chapter 3, the Drugs for HAE competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for HAE breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Drugs for HAE market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Drugs for HAE.
Chapter 14 and 15, to describe Drugs for HAE sales channel, distributors, customers, research findings and conclusion.
目錄 Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Drugs for HAE Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 C1 Esterase Inhibitors
1.3.3 Kallikrein Inhibitors
1.3.4 Bradykinin Receptor Antagonist
1.4 Market Analysis by Application
1.4.1 Overview: Global Drugs for HAE Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Hospital and Clinic
1.4.3 Pharmacy
1.4.4 Other
1.5 Global Drugs for HAE Market Size & Forecast
1.5.1 Global Drugs for HAE Consumption Value (2021 & 2025 & 2032)
1.5.2 Global Drugs for HAE Sales Quantity (2021-2032)
1.5.3 Global Drugs for HAE Average Price (2021-2032)
2 Manufacturers Profiles
2.1 Takeda Pharmaceuticals
2.1.1 Takeda Pharmaceuticals Details
2.1.2 Takeda Pharmaceuticals Major Business
2.1.3 Takeda Pharmaceuticals Drugs for HAE Product and Services
2.1.4 Takeda Pharmaceuticals Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Takeda Pharmaceuticals Recent Developments/Updates
2.2 BioCryst Pharmaceuticals
2.2.1 BioCryst Pharmaceuticals Details
2.2.2 BioCryst Pharmaceuticals Major Business
2.2.3 BioCryst Pharmaceuticals Drugs for HAE Product and Services
2.2.4 BioCryst Pharmaceuticals Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 BioCryst Pharmaceuticals Recent Developments/Updates
2.3 CSL Behring
2.3.1 CSL Behring Details
2.3.2 CSL Behring Major Business
2.3.3 CSL Behring Drugs for HAE Product and Services
2.3.4 CSL Behring Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 CSL Behring Recent Developments/Updates
2.4 Pharming Healthcare
2.4.1 Pharming Healthcare Details
2.4.2 Pharming Healthcare Major Business
2.4.3 Pharming Healthcare Drugs for HAE Product and Services
2.4.4 Pharming Healthcare Drugs for HAE Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Pharming Healthcare Recent Developments/Updates
3 Competitive Environment: Drugs for HAE by Manufacturer
3.1 Global Drugs for HAE Sales Quantity by Manufacturer (2021-2026)
3.2 Global Drugs for HAE Revenue by Manufacturer (2021-2026)
3.3 Global Drugs for HAE Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Drugs for HAE by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Drugs for HAE Manufacturer Market Share in 2025
3.4.3 Top 6 Drugs for HAE Manufacturer Market Share in 2025
3.5 Drugs for HAE Market: Overall Company Footprint Analysis
3.5.1 Drugs for HAE Market: Region Footprint
3.5.2 Drugs for HAE Market: Company Product Type Footprint
3.5.3 Drugs for HAE Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Drugs for HAE Market Size by Region
4.1.1 Global Drugs for HAE Sales Quantity by Region (2021-2032)
4.1.2 Global Drugs for HAE Consumption Value by Region (2021-2032)
4.1.3 Global Drugs for HAE Average Price by Region (2021-2032)
4.2 North America Drugs for HAE Consumption Value (2021-2032)
4.3 Europe Drugs for HAE Consumption Value (2021-2032)
4.4 Asia-Pacific Drugs for HAE Consumption Value (2021-2032)
4.5 South America Drugs for HAE Consumption Value (2021-2032)
4.6 Middle East & Africa Drugs for HAE Consumption Value (2021-2032)
5 Market Segment by Type
5.1 Global Drugs for HAE Sales Quantity by Type (2021-2032)
5.2 Global Drugs for HAE Consumption Value by Type (2021-2032)
5.3 Global Drugs for HAE Average Price by Type (2021-2032)
6 Market Segment by Application
6.1 Global Drugs for HAE Sales Quantity by Application (2021-2032)
6.2 Global Drugs for HAE Consumption Value by Application (2021-2032)
6.3 Global Drugs for HAE Average Price by Application (2021-2032)
7 North America
7.1 North America Drugs for HAE Sales Quantity by Type (2021-2032)
7.2 North America Drugs for HAE Sales Quantity by Application (2021-2032)
7.3 North America Drugs for HAE Market Size by Country
7.3.1 North America Drugs for HAE Sales Quantity by Country (2021-2032)
7.3.2 North America Drugs for HAE Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
8.1 Europe Drugs for HAE Sales Quantity by Type (2021-2032)
8.2 Europe Drugs for HAE Sales Quantity by Application (2021-2032)
8.3 Europe Drugs for HAE Market Size by Country
8.3.1 Europe Drugs for HAE Sales Quantity by Country (2021-2032)
8.3.2 Europe Drugs for HAE Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
9.1 Asia-Pacific Drugs for HAE Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Drugs for HAE Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Drugs for HAE Market Size by Region
9.3.1 Asia-Pacific Drugs for HAE Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Drugs for HAE Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
10.1 South America Drugs for HAE Sales Quantity by Type (2021-2032)
10.2 South America Drugs for HAE Sales Quantity by Application (2021-2032)
10.3 South America Drugs for HAE Market Size by Country
10.3.1 South America Drugs for HAE Sales Quantity by Country (2021-2032)
10.3.2 South America Drugs for HAE Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
11.1 Middle East & Africa Drugs for HAE Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Drugs for HAE Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Drugs for HAE Market Size by Country
11.3.1 Middle East & Africa Drugs for HAE Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Drugs for HAE Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
12.1 Drugs for HAE Market Drivers
12.2 Drugs for HAE Market Restraints
12.3 Drugs for HAE Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Drugs for HAE and Key Manufacturers
13.2 Manufacturing Costs Percentage of Drugs for HAE
13.3 Drugs for HAE Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Drugs for HAE Typical Distributors
14.3 Drugs for HAE Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Global Drugs for HAE Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Drugs for HAE Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceuticals Major Business
Table 5. Takeda Pharmaceuticals Drugs for HAE Product and Services
Table 6. Takeda Pharmaceuticals Drugs for HAE Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Takeda Pharmaceuticals Recent Developments/Updates
Table 8. BioCryst Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. BioCryst Pharmaceuticals Major Business
Table 10. BioCryst Pharmaceuticals Drugs for HAE Product and Services
Table 11. BioCryst Pharmaceuticals Drugs for HAE Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. BioCryst Pharmaceuticals Recent Developments/Updates
Table 13. CSL Behring Basic Information, Manufacturing Base and Competitors
Table 14. CSL Behring Major Business
Table 15. CSL Behring Drugs for HAE Product and Services
Table 16. CSL Behring Drugs for HAE Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. CSL Behring Recent Developments/Updates
Table 18. Pharming Healthcare Basic Information, Manufacturing Base and Competitors
Table 19. Pharming Healthcare Major Business
Table 20. Pharming Healthcare Drugs for HAE Product and Services
Table 21. Pharming Healthcare Drugs for HAE Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Pharming Healthcare Recent Developments/Updates
Table 23. Global Drugs for HAE Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 24. Global Drugs for HAE Revenue by Manufacturer (2021-2026) & (USD Million)
Table 25. Global Drugs for HAE Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 26. Market Position of Manufacturers in Drugs for HAE, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 27. Head Office and Drugs for HAE Production Site of Key Manufacturer
Table 28. Drugs for HAE Market: Company Product Type Footprint
Table 29. Drugs for HAE Market: Company Product Application Footprint
Table 30. Drugs for HAE New Market Entrants and Barriers to Market Entry
Table 31. Drugs for HAE Mergers, Acquisition, Agreements, and Collaborations
Table 32. Global Drugs for HAE Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 33. Global Drugs for HAE Sales Quantity by Region (2021-2026) & (K Units)
Table 34. Global Drugs for HAE Sales Quantity by Region (2027-2032) & (K Units)
Table 35. Global Drugs for HAE Consumption Value by Region (2021-2026) & (USD Million)
Table 36. Global Drugs for HAE Consumption Value by Region (2027-2032) & (USD Million)
Table 37. Global Drugs for HAE Average Price by Region (2021-2026) & (US$/Unit)
Table 38. Global Drugs for HAE Average Price by Region (2027-2032) & (US$/Unit)
Table 39. Global Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 40. Global Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 41. Global Drugs for HAE Consumption Value by Type (2021-2026) & (USD Million)
Table 42. Global Drugs for HAE Consumption Value by Type (2027-2032) & (USD Million)
Table 43. Global Drugs for HAE Average Price by Type (2021-2026) & (US$/Unit)
Table 44. Global Drugs for HAE Average Price by Type (2027-2032) & (US$/Unit)
Table 45. Global Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 46. Global Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 47. Global Drugs for HAE Consumption Value by Application (2021-2026) & (USD Million)
Table 48. Global Drugs for HAE Consumption Value by Application (2027-2032) & (USD Million)
Table 49. Global Drugs for HAE Average Price by Application (2021-2026) & (US$/Unit)
Table 50. Global Drugs for HAE Average Price by Application (2027-2032) & (US$/Unit)
Table 51. North America Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 52. North America Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 53. North America Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 54. North America Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 55. North America Drugs for HAE Sales Quantity by Country (2021-2026) & (K Units)
Table 56. North America Drugs for HAE Sales Quantity by Country (2027-2032) & (K Units)
Table 57. North America Drugs for HAE Consumption Value by Country (2021-2026) & (USD Million)
Table 58. North America Drugs for HAE Consumption Value by Country (2027-2032) & (USD Million)
Table 59. Europe Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 60. Europe Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 61. Europe Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 62. Europe Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 63. Europe Drugs for HAE Sales Quantity by Country (2021-2026) & (K Units)
Table 64. Europe Drugs for HAE Sales Quantity by Country (2027-2032) & (K Units)
Table 65. Europe Drugs for HAE Consumption Value by Country (2021-2026) & (USD Million)
Table 66. Europe Drugs for HAE Consumption Value by Country (2027-2032) & (USD Million)
Table 67. Asia-Pacific Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 68. Asia-Pacific Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 69. Asia-Pacific Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 70. Asia-Pacific Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 71. Asia-Pacific Drugs for HAE Sales Quantity by Region (2021-2026) & (K Units)
Table 72. Asia-Pacific Drugs for HAE Sales Quantity by Region (2027-2032) & (K Units)
Table 73. Asia-Pacific Drugs for HAE Consumption Value by Region (2021-2026) & (USD Million)
Table 74. Asia-Pacific Drugs for HAE Consumption Value by Region (2027-2032) & (USD Million)
Table 75. South America Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 76. South America Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 77. South America Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 78. South America Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 79. South America Drugs for HAE Sales Quantity by Country (2021-2026) & (K Units)
Table 80. South America Drugs for HAE Sales Quantity by Country (2027-2032) & (K Units)
Table 81. South America Drugs for HAE Consumption Value by Country (2021-2026) & (USD Million)
Table 82. South America Drugs for HAE Consumption Value by Country (2027-2032) & (USD Million)
Table 83. Middle East & Africa Drugs for HAE Sales Quantity by Type (2021-2026) & (K Units)
Table 84. Middle East & Africa Drugs for HAE Sales Quantity by Type (2027-2032) & (K Units)
Table 85. Middle East & Africa Drugs for HAE Sales Quantity by Application (2021-2026) & (K Units)
Table 86. Middle East & Africa Drugs for HAE Sales Quantity by Application (2027-2032) & (K Units)
Table 87. Middle East & Africa Drugs for HAE Sales Quantity by Country (2021-2026) & (K Units)
Table 88. Middle East & Africa Drugs for HAE Sales Quantity by Country (2027-2032) & (K Units)
Table 89. Middle East & Africa Drugs for HAE Consumption Value by Country (2021-2026) & (USD Million)
Table 90. Middle East & Africa Drugs for HAE Consumption Value by Country (2027-2032) & (USD Million)
Table 91. Drugs for HAE Raw Material
Table 92. Key Manufacturers of Drugs for HAE Raw Materials
Table 93. Drugs for HAE Typical Distributors
Table 94. Drugs for HAE Typical Customers
List of Figures
Figure 1. Drugs for HAE Picture
Figure 2. Global Drugs for HAE Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Drugs for HAE Revenue Market Share by Type in 2025
Figure 4. C1 Esterase Inhibitors Examples
Figure 5. Kallikrein Inhibitors Examples
Figure 6. Bradykinin Receptor Antagonist Examples
Figure 7. Global Drugs for HAE Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 8. Global Drugs for HAE Revenue Market Share by Application in 2025
Figure 9. Hospital and Clinic Examples
Figure 10. Pharmacy Examples
Figure 11. Other Examples
Figure 12. Global Drugs for HAE Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 13. Global Drugs for HAE Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 14. Global Drugs for HAE Sales Quantity (2021-2032) & (K Units)
Figure 15. Global Drugs for HAE Price (2021-2032) & (US$/Unit)
Figure 16. Global Drugs for HAE Sales Quantity Market Share by Manufacturer in 2025
Figure 17. Global Drugs for HAE Revenue Market Share by Manufacturer in 2025
Figure 18. Producer Shipments of Drugs for HAE by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 19. Top 3 Drugs for HAE Manufacturer (Revenue) Market Share in 2025
Figure 20. Top 6 Drugs for HAE Manufacturer (Revenue) Market Share in 2025
Figure 21. Global Drugs for HAE Sales Quantity Market Share by Region (2021-2032)
Figure 22. Global Drugs for HAE Consumption Value Market Share by Region (2021-2032)
Figure 23. North America Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 24. Europe Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 25. Asia-Pacific Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 26. South America Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 27. Middle East & Africa Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 28. Global Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 29. Global Drugs for HAE Consumption Value Market Share by Type (2021-2032)
Figure 30. Global Drugs for HAE Average Price by Type (2021-2032) & (US$/Unit)
Figure 31. Global Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 32. Global Drugs for HAE Revenue Market Share by Application (2021-2032)
Figure 33. Global Drugs for HAE Average Price by Application (2021-2032) & (US$/Unit)
Figure 34. North America Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 35. North America Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 36. North America Drugs for HAE Sales Quantity Market Share by Country (2021-2032)
Figure 37. North America Drugs for HAE Consumption Value Market Share by Country (2021-2032)
Figure 38. United States Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 39. Canada Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 40. Mexico Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 41. Europe Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 42. Europe Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 43. Europe Drugs for HAE Sales Quantity Market Share by Country (2021-2032)
Figure 44. Europe Drugs for HAE Consumption Value Market Share by Country (2021-2032)
Figure 45. Germany Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 46. France Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 47. United Kingdom Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 48. Russia Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 49. Italy Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 50. Asia-Pacific Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 51. Asia-Pacific Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 52. Asia-Pacific Drugs for HAE Sales Quantity Market Share by Region (2021-2032)
Figure 53. Asia-Pacific Drugs for HAE Consumption Value Market Share by Region (2021-2032)
Figure 54. China Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 55. Japan Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 56. South Korea Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 57. India Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 58. Southeast Asia Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 59. Australia Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 60. South America Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 61. South America Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 62. South America Drugs for HAE Sales Quantity Market Share by Country (2021-2032)
Figure 63. South America Drugs for HAE Consumption Value Market Share by Country (2021-2032)
Figure 64. Brazil Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 65. Argentina Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 66. Middle East & Africa Drugs for HAE Sales Quantity Market Share by Type (2021-2032)
Figure 67. Middle East & Africa Drugs for HAE Sales Quantity Market Share by Application (2021-2032)
Figure 68. Middle East & Africa Drugs for HAE Sales Quantity Market Share by Country (2021-2032)
Figure 69. Middle East & Africa Drugs for HAE Consumption Value Market Share by Country (2021-2032)
Figure 70. Turkey Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 71. Egypt Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 72. Saudi Arabia Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 73. South Africa Drugs for HAE Consumption Value (2021-2032) & (USD Million)
Figure 74. Drugs for HAE Market Drivers
Figure 75. Drugs for HAE Market Restraints
Figure 76. Drugs for HAE Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Drugs for HAE in 2025
Figure 79. Manufacturing Process Analysis of Drugs for HAE
Figure 80. Drugs for HAE Industrial Chain
Figure 81. Sales Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Global Info Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們